Total Payments
$511,301
2024 Payments
$107,637
Companies
44
Transactions
773
Medicare Patients
6,949
Medicare Billing
$2.3M
Payment Breakdown by Category
Consulting$203,304 (39.8%)
Other$146,078 (28.6%)
Research$96,312 (18.8%)
Travel$41,158 (8.0%)
Food & Beverage$23,617 (4.6%)
Gifts$687.67 (0.1%)
Education$144.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $203,304 | 68 | 39.8% |
| Unspecified | $96,312 | 14 | 18.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $77,733 | 18 | 15.2% |
| Honoraria | $43,950 | 17 | 8.6% |
| Travel and Lodging | $41,158 | 111 | 8.0% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $24,395 | 5 | 4.8% |
| Food and Beverage | $23,617 | 534 | 4.6% |
| Gift | $687.67 | 3 | 0.1% |
| Education | $144.00 | 3 | 0.0% |
Payments by Type
General
$414,989
759 transactions
Research
$96,312
14 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Endo Pharmaceuticals Inc. | $108,492 | 52 | $0 (2022) |
| STRATA Skin Sciences, Inc. | $52,985 | 13 | $0 (2023) |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $44,357 | 94 | $0 (2024) |
| MERZ NORTH AMERICA, INC. | $44,267 | 87 | $0 (2024) |
| VYNE Pharmaceuticals Inc. | $39,721 | 37 | $0 (2021) |
| Arcutis Biotherapeutics, Inc. | $37,471 | 35 | $0 (2024) |
| Medline Industries, Inc. | $36,512 | 41 | $0 (2021) |
| MIMEDX Group, Inc. | $32,920 | 15 | $0 (2024) |
| PFIZER INC. | $23,424 | 33 | $0 (2024) |
| Regeneron Pharmaceuticals, Inc. | $19,237 | 17 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $107,637 | 137 | MIMEDX Group, Inc. ($32,920) |
| 2023 | $80,525 | 80 | STRATA Skin Sciences, Inc. ($52,950) |
| 2022 | $59,125 | 45 | Endo Pharmaceuticals Inc. ($54,174) |
| 2021 | $26,015 | 79 | VYNE Pharmaceuticals Inc. ($20,085) |
| 2020 | $51,648 | 57 | Endo Pharmaceuticals Inc. ($24,610) |
| 2019 | $68,983 | 151 | Ortho Dermatologics, a division of Bausch Health US, LLC ($23,509) |
| 2018 | $44,650 | 108 | Ortho Dermatologics, a division of Bausch Health US, LLC ($15,490) |
| 2017 | $72,718 | 116 | MERZ NORTH AMERICA, INC. ($32,768) |
All Payment Transactions
773 individual payment records from CMS Open Payments — Page 1 of 31
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | Consulting Fee | Cash or cash equivalent | $8,029.00 | General |
| Category: ONCOLOGY | ||||||
| 12/20/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | Consulting Fee | Cash or cash equivalent | $4,588.00 | General |
| Category: ONCOLOGY | ||||||
| 12/20/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | Consulting Fee | Cash or cash equivalent | $1,147.00 | General |
| Category: ONCOLOGY | ||||||
| 12/17/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $3.85 | General |
| Category: Immunology | ||||||
| 12/16/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $8.57 | General |
| Category: FACIAL AESTHETICS | ||||||
| 12/13/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | Travel and Lodging | In-kind items and services | $461.35 | General |
| Category: ONCOLOGY | ||||||
| 12/13/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $105.90 | General |
| Category: ONCOLOGY | ||||||
| 12/13/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $97.89 | General |
| Category: ONCOLOGY | ||||||
| 12/13/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $76.40 | General |
| Category: ONCOLOGY | ||||||
| 12/13/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $39.41 | General |
| Category: ONCOLOGY | ||||||
| 12/13/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $39.41 | General |
| Category: ONCOLOGY | ||||||
| 12/13/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $35.52 | General |
| Category: ONCOLOGY | ||||||
| 12/11/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $42.07 | General |
| Category: Immunology | ||||||
| 12/05/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $18.86 | General |
| Category: FACIAL AESTHETICS | ||||||
| 12/04/2024 | Arcutis Biotherapeutics, Inc. | Zoryve (Drug) | Consulting Fee | Cash or cash equivalent | $3,375.00 | General |
| Category: Dermatology | ||||||
| 12/04/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $27.89 | General |
| Category: Immunology | ||||||
| 12/02/2024 | MIMEDX Group, Inc. | — | Consulting Fee | Cash or cash equivalent | $4,125.00 | General |
| 12/02/2024 | MIMEDX Group, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,437.50 | General |
| 12/02/2024 | MIMEDX Group, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,125.00 | General |
| 12/02/2024 | MIMEDX Group, Inc. | — | Travel and Lodging | Cash or cash equivalent | $189.38 | General |
| 12/02/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $43.72 | General |
| Category: Immunology | ||||||
| 12/02/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $14.55 | General |
| Category: Immunology | ||||||
| 11/27/2024 | Solta Medical, a division of Bausch Health US, LLC | THERMAGE FLX | Consulting Fee | Cash or cash equivalent | $6,960.00 | General |
| 11/25/2024 | SUN PHARMACEUTICAL INDUSTRIES INC. | ILUMYA (Biological) | Food and Beverage | In-kind items and services | $25.38 | General |
| Category: Dermatology | ||||||
| 11/20/2024 | Arcutis Biotherapeutics, Inc. | Zoryve (Drug) | Consulting Fee | Cash or cash equivalent | $2,625.00 | General |
| Category: Dermatology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase 2B, Open-Label Study to Explore Tissue Histopathology Following Subcutaneous Injection of Collagenase Clostridium Histolyticum Using An Abdominoplasty Model | Endo Pharmaceuticals Inc. | $54,145 | 2 |
| Not Specific to one study | Endo Pharmaceuticals Inc. | $39,781 | 11 |
| EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) | Eli Lilly and Company | $2,387 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 26 | 1,879 | 2,712 | $2.3M | $618,512 |
| 2022 | 25 | 1,792 | 2,429 | $2.3M | $621,099 |
| 2021 | 26 | 1,889 | 2,598 | $2.3M | $657,055 |
| 2020 | 23 | 1,389 | 2,223 | $1.5M | $412,101 |
Total Patients
6,949
Total Services
9,962
Medicare Billing
$2.3M
Procedure Codes
101
All Medicare Procedures & Services
101 procedure records from CMS Medicare Utilization — Page 3 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2022 | 50 | 293 | $16,990 | $1,651 | 9.7% |
| 15275 | Application of skin substitute graft to wound of face, scalp, eyelids, mouth, neck, ears, around eyes, genitals, hands, feet, fingers, or toes, 25.0 sq cm or less of wound 100.0 sq cm or less | Office | 2022 | 16 | 17 | $9,486 | $1,471 | 15.5% |
| 17311 | Removal and microscopic examination of growth of the head, neck, hands, feet, or genitals (first stage, up to 5 tissue blocks) | Office | 2021 | 359 | 444 | $728,567 | $190,916 | 26.2% |
| 17312 | Removal and microscopic examination of growth of the head, neck, hands, feet, or genitals | Office | 2021 | 214 | 380 | $374,134 | $135,815 | 36.3% |
| 15260 | Relocation of patient skin to nose, ears, eyelids, and/or lips (20 sq centimeters or less) | Office | 2021 | 100 | 101 | $323,191 | $86,476 | 26.8% |
| 15240 | Relocation of patient skin to forehead, cheeks, chin, mouth, neck, underarms, genitals, hands, and/or feet (20 sq centimeters or less) | Office | 2021 | 42 | 43 | $137,514 | $35,107 | 25.5% |
| 14040 | Tissue transfer repair of wound (10 sq centimeters or less) of the forehead, cheeks, chin, mouth, neck, underarms, genitals, hands, and/or feet | Office | 2021 | 37 | 37 | $91,137 | $23,551 | 25.8% |
| 14041 | Tissue transfer repair of wound (10.1 to 30.0 sq centimeters) of the forehead, cheeks, chin, mouth, neck, underarms, genitals, hands, and/or feet | Office | 2021 | 28 | 28 | $86,744 | $22,431 | 25.9% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 204 | 307 | $60,358 | $21,987 | 36.4% |
| 17313 | Removal and microscopic examination of growth of the trunk, arms, or legs (first stage, up to 5 tissue blocks) | Office | 2021 | 31 | 38 | $56,240 | $19,191 | 34.1% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 203 | 203 | $52,374 | $17,829 | 34.0% |
| 13132 | Repair of wound (2.6 to 7.5 centimeters) of forehead, cheeks, chin, mouth, neck, underarms, genitals, hands, and/or feet | Office | 2021 | 68 | 72 | $94,964 | $15,619 | 16.4% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 105 | 105 | $38,609 | $15,107 | 39.1% |
| 14021 | Tissue transfer repair of wound (10.1 to 30.0 sq centimeters) of the scalp, arms, and/or legs | Office | 2021 | 14 | 14 | $39,214 | $10,642 | 27.1% |
| 14060 | Tissue transfer repair of wound (10 sq centimeters or less) of eyelids, nose, ears, and/or lips | Office | 2021 | 15 | 15 | $39,300 | $10,012 | 25.5% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Office | 2021 | 118 | 163 | $21,906 | $7,306 | 33.4% |
| 14020 | Tissue transfer repair of wound (10 sq centimeters or less) of the scalp, arms, and/or legs | Office | 2021 | 11 | 11 | $25,190 | $6,699 | 26.6% |
| 17004 | Destruction of 15 or more premalignant skin growths | Office | 2021 | 29 | 47 | $21,669 | $6,305 | 29.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 54 | 58 | $17,190 | $5,867 | 34.1% |
| 15004 | Preparation of graft site of face, scalp, eyelids, mouth, neck, ears, eye region, genitals, hands, feet, and/or multiple fingers or toes (first 100 sq cm or 1% body area of infants and children) | Office | 2021 | 16 | 16 | $13,792 | $5,350 | 38.8% |
| 11102 | Tangential biopsy of single skin lesion | Office | 2021 | 54 | 63 | $13,482 | $5,117 | 38.0% |
| 13121 | Repair of wound (2.6 to 7.5 centimeters) of scalp, arms, and/or legs | Office | 2021 | 20 | 20 | $33,840 | $4,483 | 13.2% |
| 17000 | Destruction of skin growth | Office | 2021 | 51 | 65 | $14,302 | $2,767 | 19.3% |
| 17110 | Destruction of up to 14 skin growths | Office | 2021 | 19 | 22 | $5,788 | $1,972 | 34.1% |
| 15275 | Application of skin substitute (wound surface up to 100 sq cm) to face, scalp, eyelids, mouth, neck, ears, eye region, genitals, hands, feet, and/or multiple fingers or toes (first 25 sq cm or less) | Office | 2021 | 21 | 22 | $12,276 | $1,902 | 15.5% |
About Dr. Ashish Bhatia, M.D
Dr. Ashish Bhatia, M.D is a Dermatology healthcare provider based in Itasca, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/18/2005. The National Provider Identifier (NPI) number assigned to this provider is 1073595690.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ashish Bhatia, M.D has received a total of $511,301 in payments from pharmaceutical and medical device companies, with $107,637 received in 2024. These payments were reported across 773 transactions from 44 companies. The most common payment nature is "Consulting Fee" ($203,304).
As a Medicare-enrolled provider, Bhatia has provided services to 6,949 Medicare beneficiaries, totaling 9,962 services with total Medicare billing of $2.3M. Data is available for 4 years (2020–2023), covering 101 distinct procedure/service records.
Ad
Practice Information
- Specialty Dermatology
- Other Specialties MOHS-Micrographic Surgery, Procedural Dermatology
- Location Itasca, IL
- Active Since 11/18/2005
- Last Updated 02/25/2025
- Taxonomy Code 207N00000X
- Entity Type Individual
- NPI Number 1073595690
Products in Payments
- XTRAC (Device) $52,985
- Zoryve (Drug) $26,808
- AMZEEQ (Drug) $25,497
- CIBINQO (Drug) $20,982
- LIBTAYO (Biological) $19,268
- ALTRENO (Drug) $19,120
- ZILXI (Drug) $14,224
- SILIQ (Drug) $12,531
- THERMAGE FLX $7,389
- QBREXZA (Drug) $6,072
- CELLUTOME (Device) $5,742
- KYBELLA (Biological) $4,560
- RETIN-A-MICRO (Drug) $4,458
- ARAZLO (Drug) $2,800
- TALTZ (Drug) $2,727
- RHOFADE (Drug) $2,397
- EUCRISA (Drug) $1,997
- BOTOX COSMETIC (Biological) $1,837
- Dermatology and Wound Care (Medical Supply) $1,679
- XEOMIN (Biological) $1,299
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.